Piguamerin
Plasma kallikrein and trypsin inhibitor from Korean leech — anti-inflammatory and antithrombotic research.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Plasma kallikrein and trypsin inhibitor from Korean leech — anti-inflammatory and antithrombotic research.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
Piguamerin's in vitro inhibition of plasma kallikrein and trypsin does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Molecular weight
- 5,860 Da
- Source species
- Hirudo nipponia
- Discovered
- 1998 · Kim DR et al.
Biological Targets
- → plasma kallikrein
- → trypsin
Key Citations
- Kim DR, Kang KW (1998), Eur J Biochem · PMID 9688284
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.